Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H8NO2.Na |
Molecular Weight | 173.1444 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC(=O)NC1=CC=C([O-])C=C1
InChI
InChIKey=QOGCGSWEVWTHNX-UHFFFAOYSA-M
InChI=1S/C8H9NO2.Na/c1-6(10)9-7-2-4-8(11)5-3-7;/h2-5,11H,1H3,(H,9,10);/q;+1/p-1
Acetaminophen, also known as paracetamol, is commonly used for its analgesic and antipyretic effects. Its therapeutic effects are similar to salicylates, but it lacks anti-inflammatory, antiplatelet, and gastric ulcerative effects. Acetaminophen (USAN) or Paracetamol (INN) is a widely used analgesic and antipyretic drug that is used for the relief of fever, headaches, and other minor aches and pains. It is a major ingredient in numerous cold and flu medications and many prescription analgesics. It is extremely safe in standard doses, but because of its wide availability, deliberate or accidental overdoses are not uncommon. Acetaminophen, unlike other common analgesics such as aspirin and ibuprofen, has no anti-inflammatory properties or effects on platelet function, and it is not a member of the class of drugs known as non-steroidal anti-inflammatory drugs or NSAIDs. At therapeutic doses, acetaminophen does not irritate the lining of the stomach nor affect blood coagulation, kidney function, or the fetal ductus arteriosus (as NSAIDs can). Acetaminophen is thought to act primarily in the CNS, increasing the pain threshold by inhibiting both isoforms of cyclooxygenase, COX-1, COX-2, and COX-3 enzymes involved in prostaglandin (PG) synthesis. Unlike NSAIDs, acetaminophen does not inhibit cyclooxygenase in peripheral tissues and, thus, has no peripheral anti-inflammatory affects. Acetaminophen indirectly blocks COX, and that this blockade is ineffective in the presence of peroxides. This might explain why acetaminophen is effective in the central nervous system and in endothelial cells but not in platelets and immune cells, which have high levels of peroxides. Studies also report data suggesting that acetaminophen selectively blocks a variant of the COX enzyme that is different from the known variants COX-1 and COX-2. This enzyme is now referred to as COX-3. Its exact mechanism of action is still poorly understood, but future research may provide further insight into how it works. The antipyretic properties of acetaminophen are likely due to direct effects on the heat-regulating centers of the hypothalamus resulting in peripheral vasodilation, sweating and hence heat dissipation.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=15662292 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | TYLENOL Approved UseUses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever Launch Date1994 |
|||
Palliative | TYLENOL Approved UseUses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever Launch Date1994 |
|||
Palliative | TYLENOL Approved UseUses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever Launch Date1994 |
|||
Palliative | TYLENOL Approved UseUses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever Launch Date1994 |
|||
Palliative | TYLENOL Approved UseUses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever Launch Date1994 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
28 μg/mL |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ACETAMINOPHEN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
43 μg × h/mL |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ACETAMINOPHEN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.4 h |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
ACETAMINOPHEN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/12388633/ Page: - |
no | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes [Ki 2300 uM] | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes [Ki 5300 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 6.0 |
major | |||
Page: 6.0 |
no | |||
Page: 6.0 |
no | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
no | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
no | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
no | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18232020/ Page: - |
yes [Km 1500 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18232020/ Page: - |
yes [Km 1900 uM] | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes [Km 2300 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18232020/ Page: - |
yes [Km 3700 uM] | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes [Km 4000 uM] | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes [Km 5500 uM] | |||
Page: 6.0 |
yes | |||
Page: 6.0 |
yes | |||
Page: 6.0 |
yes | |||
Page: 6.0 |
yes | |||
Page: 6.0 |
yes | |||
Page: 6.0 |
yes | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes | |||
Sources: https://pubs.acs.org/doi/10.1021/tx050317i Page: - |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
The degradation of paracetamol (4-hydroxyacetanilide) and other substituted acetanilides by a Penicillium species. | 1975 |
|
Massive hemolysis caused by acetaminophen. Positive determination by direct Coombs test. | 1976 Dec 13 |
|
An experimental study on the disorders of hepatic hemodynamics and changes of plasma histamine in dogs with fulminant hepatic failure. | 1998 |
|
Risk factors for acetaminophen and nimesulide intolerance in patients with NSAID-induced skin disorders. | 1999 Jun |
|
Characteristics and risk factors of acetaminophen-induced hepatitis in Taiwan. | 1999 Jun |
|
Enhancement of low density lipoprotein catabolism by non-steroidal anti-inflammatory drugs in cultured HepG2 cells. | 1999 May 21 |
|
Accidental paracetamol overdosing and fulminant hepatic failure in children. | 1999 Nov 1 |
|
The potential of acetaminophen as a prodrug in gene-directed enzyme prodrug therapy. | 2000 Apr |
|
The hepatic inflammatory response after acetaminophen overdose: role of neutrophils. | 2000 Apr |
|
A hepatotoxic dose of acetaminophen modulates expression of BCL-2, BCL-X(L), and BCL-X(S) during apoptotic and necrotic death of mouse liver cells in vivo. | 2000 Jan |
|
Acetaminophen inhibits iNOS gene expression in RAW 264.7 macrophages: differential regulation of NF-kappaB by acetaminophen and salicylates. | 2000 Jun 16 |
|
Deafness associated with abuse of hydrocodone/acetaminophen. | 2000 Jun 27 |
|
Long-chain hydroxydicarboxylic aciduria, carnitine depletion and acetaminophen exposure. | 2000 Mar |
|
Effect of chronic analgesic exposure on the central serotonin system: a possible mechanism of analgesic abuse headache. | 2000 May |
|
Mechanism of action of acetaminophen: is there a cyclooxygenase 3? | 2000 Oct |
|
Peroxisome proliferator-activated receptor alpha-null mice lack resistance to acetaminophen hepatotoxicity following clofibrate exposure. | 2000 Oct |
|
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. | 2001 |
|
The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. | 2001 |
|
p-Aminophenol-induced liver toxicity: tentative evidence of a role for acetaminophen. | 2001 |
|
Management of drug-induced liver disease. | 2001 Feb |
|
Clinical trial of an air-circulating cooling blanket for fever control in critically ill neurologic patients. | 2001 Feb 13 |
|
Hemolytic anemia after acetaminophen overdose in patient with glucose-6-phosphate dehydrogenase deficiency. | 2001 Feb 15 |
|
[About paracetamol again]. | 2001 Feb 18 |
|
The role of acetaminophen in the management of patients with osteoarthritis. | 2001 Feb 19 |
|
ABC of diseases of liver, pancreas, and biliary system. Other causes of parenchymal liver disease. | 2001 Feb 3 |
|
Simultaneous determination of paracetamol and methocarbamol in tablets by ratio spectra derivative spectrophotometry and LC. | 2001 Jan |
|
NSAID impairment of orthodontic tooth movement. | 2001 Jan |
|
Separation of cold medicine ingredients by capillary electrophoresis. | 2001 Jan |
|
Single and multiple dose pharmacokinetics of acetaminophen (paracetamol) in polymedicated very old patients with rheumatic pain. | 2001 Jan |
|
Successful use of propranolol in migraine associated with electroconvulsive therapy. | 2001 Jan |
|
A comparison of the effect of nitroparacetamol and paracetamol on liver injury. | 2001 Jan |
|
One hundred percent online identity check of pharmaceutical products by near-infrared spectroscopy on the packaging line. | 2001 Jan |
|
Preoperative rectal diclofenac versus paracetamol for tonsillectomy: effects on pain and blood loss. | 2001 Jan |
|
Treatment with paracetamol in infants. | 2001 Jan |
|
Gastric emptying in diabetic gastroparetic dogs: ffects of SK-951,a novel prokinetic agent. | 2001 Jan |
|
Safety of childhood acetaminophen overdose. | 2001 Jan |
|
Treatment of acetaminophen ingestion with a superactivated charcoal-cola mixture. | 2001 Jan |
|
Effects of rectally administered paracetamol on infants delivered by vacuum extraction. | 2001 Jan |
|
High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. | 2001 Jan |
|
Causes of Alzheimer's disease: paracetamol (acetaminophen) today? Amphetamines tomorrow? | 2001 Jan |
|
Using evidence from different sources: an example using paracetamol 1000 mg plus codeine 60 mg. | 2001 Jan 10 |
|
Allergic reactions due to ibuprofen in children. | 2001 Jan-Feb |
|
Pharmacokinetics of oral diclofenac and acetaminophen in children after surgery. | 2001 Mar |
|
Experimental and theoretical microdialysis studies of in situ metabolism. | 2001 Mar |
|
Pediatric acetaminophen poisoning. | 2001 Mar |
Patents
Sample Use Guides
2 caplets every 8 hours with water; don't take more than 6 caplets in 24 hours
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10751557
A time- and concentration-dependent decrease in intracellular GSH occurred in freshly isolated type II pneumocytes and alveolar macrophages exposed to subtoxic (= 1 mM) APAP concentrations.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
V9E6HW6ZAG
Created by
admin on Sat Dec 16 18:58:13 GMT 2023 , Edited by admin on Sat Dec 16 18:58:13 GMT 2023
|
PRIMARY | |||
|
16958-94-4
Created by
admin on Sat Dec 16 18:58:13 GMT 2023 , Edited by admin on Sat Dec 16 18:58:13 GMT 2023
|
PRIMARY | |||
|
23667500
Created by
admin on Sat Dec 16 18:58:13 GMT 2023 , Edited by admin on Sat Dec 16 18:58:13 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD